skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Many companies are looking to core-asset strengthening, underperforming asset divestments, and cost saving tax inversions.
Datamonitor Healthcare explores the value in the recent flurry of deals, shedding light on the key incentives and how they may influence the market and future deal-making.

 

This white paper includes analysis of the following deals:

  • Pfizer/AstraZeneca – Pfizer’s courtship of AstraZeneca for complementary assets and tax benefits.
  • Novartis/GSK – Novartis and GlaxoSmithKline restructure through asset swap deals.
  • Bayer/Merck – Bayer to pay $14.2bn for Merck’s consumer care division.
  • Valeant/Allergan – Valeant partners hedge fund in attempted Allergan takeover.
  • Market Outlook – How do these transactions change the market?
2014 M&A Review

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: